Literature DB >> 15697217

Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA.

Eric S Day1, Teresa G Cachero, Fang Qian, Yaping Sun, Dingyi Wen, Marc Pelletier, Yen-Ming Hsu, Adrian Whitty.   

Abstract

BAFF (B cell activating factor of the TNF family, also known as BlyS and TALL-1), a TNF family cytokine critical for the development and function of B cells, has been reported to bind to three receptors, BCMA (B cell maturation protein), TACI (transmembrane activator and CAML [calcium-modulator and cyclophilin ligand] interactor), and BAFFR (BAFF receptor), but with widely conflicting values for the affinity and selectivity of binding. BCMA and TACI additionally bind APRIL (a proliferation-inducing ligand), the TNF family ligand most homologous to BAFF. Using soluble, monomeric forms of the receptors, we demonstrate that BAFFR binds BAFF with K(D) approximately 16 nM, while BCMA binds with K(D) approximately 1.6 microM, indicating a approximately 100-fold selectivity for binding to BAFFR over BCMA. APRIL shows the opposite selectivity, binding to BCMA with K(D) approximately 16 nM while showing no detectable affinity for BAFFR (K(D) > 3 microM). The binding of BAFF or APRIL to these receptors is highly sensitive to assay-dependent avidity effects, likely explaining the widely ranging affinity values reported in the literature. Binding of BAFF to BCMA-Fc, a bivalent fusion protein consisting of the extracellular domain of BCMA fused to the hinge and CH1 and CH2 domains of human IgG1, in solution or coated onto an ELISA plate gave apparent binding affinities of approximately 0.63 and approximately 0.15 nM, respectively, compared to values of K(D(app)) <or= 30 and approximately 100 pM for the corresponding BAFFR/IgG1 fusion protein, BAFFR-Fc. The high selectivity of BAFF for BAFFR versus BCMA is thus partly obscured in these multivalent assays. The intrinsically high selectivity inferred from the measurements with monomeric receptor correlates well with in vivo data from knockout mice, providing a possible explanation for the observations that interruption of the BAFFR gene in the A/WySnJ mouse produces a phenotype similar to the BAFF knockout mouse, while the BCMA knockout mouse has no discernible B cell phenotype.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15697217     DOI: 10.1021/bi048227k

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  62 in total

1.  Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity.

Authors:  Jianying Dong; Arlene Sereno; William B Snyder; Brian R Miller; Susan Tamraz; Adam Doern; Michael Favis; Xiufeng Wu; Hon Tran; Emma Langley; Ingrid Joseph; Antonio Boccia; Rebecca Kelly; Kathleen Wortham; Qin Wang; Lisa Berquist; Flora Huang; Sharon X Gao; Ying Zhang; Alexey Lugovskoy; Shelly Martin; Heather Gouvis; Steven Berkowitz; Gisela Chiang; Mitchell Reff; Scott M Glaser; Kandasamy Hariharan; Stephen J Demarest
Journal:  J Biol Chem       Date:  2010-12-01       Impact factor: 5.157

2.  Binding Studies of TNF Receptor Superfamily (TNFRSF) Receptors on Intact Cells.

Authors:  Isabell Lang; Simone Füllsack; Agnes Wyzgol; Andrea Fick; Johannes Trebing; José Antonio Carmona Arana; Viktoria Schäfer; Daniela Weisenberger; Harald Wajant
Journal:  J Biol Chem       Date:  2015-12-31       Impact factor: 5.157

Review 3.  Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease.

Authors:  Robert C Rickert; Julia Jellusova; Ana V Miletic
Journal:  Immunol Rev       Date:  2011-11       Impact factor: 12.988

4.  Blockade of BAFF Receptor BR3 on T Cells Enhances Their Activation and Cytotoxicity.

Authors:  Debra D Bloom; Sofiya Reshetylo; Cassandra Nytes; Claudia T Goodsett; Peiman Hematti
Journal:  J Immunother       Date:  2018-06       Impact factor: 4.456

Review 5.  Toward Small-Molecule Inhibition of Protein-Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions.

Authors:  Damir Bojadzic; Peter Buchwald
Journal:  Curr Top Med Chem       Date:  2018       Impact factor: 3.295

Review 6.  New roles for the BLyS/BAFF family in antigen-experienced B cell niches.

Authors:  Radhika Goenka; Jean L Scholz; Vishal J Sindhava; Michael P Cancro
Journal:  Cytokine Growth Factor Rev       Date:  2014-01-10       Impact factor: 7.638

Review 7.  Behçet's syndrome pathophysiology and potential therapeutic targets.

Authors:  Giacomo Emmi; Elena Silvestri; Danilo Squatrito; Mario Milco D'Elios; Lucia Ciucciarelli; Domenico Prisco; Lorenzo Emmi
Journal:  Intern Emerg Med       Date:  2014-01-12       Impact factor: 3.397

Review 8.  The function of BAFF on T helper cells in autoimmunity.

Authors:  Maogen Chen; Xiaohong Lin; Ya Liu; Qiang Li; Yiling Deng; Zhongmin Liu; David Brand; Zhiyong Guo; Xiaoshun He; Bernhard Ryffel; Song Guo Zheng
Journal:  Cytokine Growth Factor Rev       Date:  2013-12-24       Impact factor: 7.638

9.  The design and characterization of receptor-selective APRIL variants.

Authors:  Fiona C Kimberley; Almer M van der Sloot; Marco Guadagnoli; Katherine Cameron; Pascal Schneider; J Arnoud Marquart; Miranda Versloot; Luis Serrano; Jan Paul Medema
Journal:  J Biol Chem       Date:  2012-09-07       Impact factor: 5.157

Review 10.  Understanding cytokine and growth factor receptor activation mechanisms.

Authors:  Mariya Atanasova; Adrian Whitty
Journal:  Crit Rev Biochem Mol Biol       Date:  2012-10-09       Impact factor: 8.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.